| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_653c418e41edbb4e1ce8bc5e53e70cec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5febe0b1aa9d237b1cb7b71f94b01743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21e44c422ca347e2ebf66fa41e1c9901
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ba2e55dccd99087392a182ae92f3a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93ec558c6f6e744c2015a317d7c3e361
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c48186d66e51dfd9862dc62e6fcf4e4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f03a7c048551be1e2522604ae510a6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bd78e5c60d6b235518d7753da43939d |
| publicationDate |
2019-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110256574-A |
| titleOfInvention |
Fusion polypeptide and its application in the preparation of antidepressant and neurodegenerative disease drugs |
| abstract |
The disclosure belongs to the field of biotechnology, and specifically relates to a 9R-eIF4A-VI fusion polypeptide and its application in the preparation of antidepressant drugs. Public studies have confirmed that PDCD4 can bind to eukaryotic cell translation initiation factor (eIF4A) to inhibit the expression of brain-derived neurotrophic factor (BDNF), hinder the repair of damaged neuron cells and synaptic transmission, and aggravate the symptoms of depression patients. This disclosure screened and identified several domains that bind PDCD4 and eIF4A. By fusing the transmembrane sequence and a segment of domains on eIF4A, a fusion polypeptide with interference effect was obtained. Experimental verification shows that the fusion polypeptide can effectively interfere with the binding of PDCD4 and eIF4A , and has good transmembrane efficiency and stability, and can be applied to the preparation of antidepressant drugs, which is of great significance. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111116756-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113307862-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111116756-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022246930-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113307862-B |
| priorityDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |